EyeConic: Qualification for Cone-Optogenetics

Qualification for Cone-Optogenetics (EyeConic)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05294978

Enrollment

1000

Registered

2022-03-24

Start date

2021-07-01

Completion date

2026-12-31

Last updated

2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Dystrophies

Keywords

Cone-Optogenetics, Rod-cone Dystrophy, Cone-rod Dystrophy, Generalized retinal dystrophies, Inherited retinal disease

Brief summary

This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

Detailed description

In a subset of patients with inherited retinal dystrophies (IRDs), cones lose their light-sensitive outer segments but remain alive in a dormant stage. This creates an opportunity to resensitize them through targeted optogenetic tools. However, the true proportion of low vision patients harboring dormant, non-functional cones, is currently unknown. The worldwide multicenter retrospective study (EyeConic) aims to estimate the proportion of low vision patients with remaining cone cell bodies for the first time.

Interventions

DIAGNOSTIC_TESTOptical coherence tomography (OCT)

Data of macular optical coherence tomography (OCT)

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

(patients): * Diagnosis of generalized IRD * Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye * Availability of macular optical coherence tomography (OCT) Inclusion Criteria (controls): * Normal ophthalmic findings * Availability of macular optical coherence tomography (OCT)

Exclusion criteria

(all): * Other eye diseases with a significant effect on vision or retinal structure * Extraocular disease affecting retinal structure such as neurodegenerative diseases

Design outcomes

Primary

Measure	Time frame	Description
OCT - Central retinal volume	Baseline (about 10 minutes)	Number of participants with preserved central retinal volume

Countries

China, Germany, Hungary, Italy, Switzerland, United Kingdom, United States

Contacts

Primary ContactLucas Janeschitz-Kriegl, MD

lucas.janeschitz@iob.ch+41787494373

Backup ContactTiana Koottungal

tiana.koottungal@iob.ch+41788486737

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026